Forkhead box protein M1 (FOXM1) is often overexpressed in human cancers and strongly associated with therapy resistance and less good patient survival. The chemotherapy options for patients with the most aggressive types of solid cancers remain very limited because of the acquired drug resistance, making the therapy less effective. NPM1 mutation through the inactivation of FOXM1 via FOXM1 relocalization to the cytoplasm confers more favorable treatment outcomes for AML patients, confirming FOXM1 as a crucial target to overcome drug resistance. Pharmacological inhibition of FOXM1 could be a promising approach to sensitize therapy-resistant cancers. Here, we explore a novel FOXM1 inhibitor STL001, a first-generation modification drug of our previously reported FOXM1 inhibitor STL427944. STL001 preserves the mode of action of the STL427944; however, STL001 is up to 50 times more efficient in reducing FOXM1 activity in a variety of solid cancers. The most conventional cancer therapies studied here induce FOXM1 overexpression in solid cancers. The therapy-induced FOXM1 overexpression may explain the failure or reduced efficacy of these drugs in cancer patients. Interestingly, STL001 increased the sensitivity of cancer cells to conventional cancer therapies by suppressing both the high-endogenous and drug-induced FOXM1. Notably, STL001 does not provide further sensitization to FOXM1-KD cancer cells, suggesting that the sensitization effect is conveyed specifically through FOXM1 suppression. RNA-seq and gene set enrichment studies revealed prominent suppression of FOXM1-dependent pathways and gene ontologies. Also, gene regulation by STL001 showed extensive overlap with FOXM1-KD, suggesting a high selectivity of STL001 toward the FOXM1 regulatory network. A completely new activity of FOXM1, mediated through steroid/cholesterol biosynthetic process and protein secretion in cancer cells was also detected. Collectively, STL001 offers intriguing translational opportunities as combination therapies targeting FOXM1 activity in a variety of human cancers driven by FOXM1.

Department of Computational and Systems Biology University of Pittsburgh Chicago IL USA

Northwestern University Chicago IL USA

Oregon Health and Science University Knight Cancer Institute School of Medicine Chicago IL USA

The Czech Advanced Technology and Research Institute of Palacký University Chicago IL USA

University of Illinois at Chicago Department of Medicine Chicago IL USA

Update Of

Res Sq. 2024 Jan 11:rs.3.rs-3711759. doi: 10.21203/rs.3.rs-3711759/v2. PubMed

See more in PubMed

Kalathil D, John S, Nair AS. FOXM1 and cancer: faulty cellular signaling derails homeostasis. Front Oncol. 2021;10:626836. doi: 10.3389/fonc.2020.626836. PubMed DOI PMC

Liu C, Barger CJ, Karpf AR. FOXM1: a multifunctional oncoprotein and emerging therapeutic target in ovarian cancer. Cancers (Basel). 2021;13:3065. doi: 10.3390/cancers13123065. PubMed DOI PMC

Zhang YL, Ma Y, Zeng YQ, Liu Y, He EP, Liu YT, et al. A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics. Ann Transl Med. 2021;9:1704. doi: 10.21037/atm-21-5271. PubMed DOI PMC

Halasi M, Gartel AL. Targeting FOXM1 in cancer. Biochem Pharmacol. 2013;85:644–52. doi: 10.1016/j.bcp.2012.10.013. PubMed DOI

Chesnokov MS, Halasi M, Borhani S, Arbieva Z, Shah BN, Oerlemans R, et al. Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells. Cell Death Dis. 2021;12:704. doi: 10.1038/s41419-021-03978-0. PubMed DOI PMC

Li L, Wu D, Yu Q, Li L, Wu P. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:32298–308. doi: 10.18632/oncotarget.15764. PubMed DOI PMC

Song L, Wang X, Feng Z. Overexpression of FOXM1 as a target for malignant progression of esophageal squamous cell carcinoma. Oncol Lett. 2018;15:5910–4. PubMed PMC

Qin Q, Chen H, Xu H, Zhang X, Chen J, Zhang C, et al. FoxM1 knockdown enhanced radiosensitivity of esophageal cancer by inducing apoptosis. J Cancer. 2023;14:454–63. doi: 10.7150/jca.76671. PubMed DOI PMC

Liao GB, Li XZ, Zeng S, Liu C, Yang SM, Yang L, et al. Regulation of the master regulator FOXM1 in cancer. Cell Commun Signal. 2018;16:57. doi: 10.1186/s12964-018-0266-6. PubMed DOI PMC

Zona S, Bella L, Burton MJ, Nestal de Moraes G, Lam EW. FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. Biochim Biophys Acta. 2014;1839:1316–22. doi: 10.1016/j.bbagrm.2014.09.016. PubMed DOI PMC

Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res. 2013;119:191–419. doi: 10.1016/B978-0-12-407190-2.00016-2. PubMed DOI

Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7:847–59. doi: 10.1038/nrc2223. PubMed DOI

Saba R, Alsayed A, Zacny JP, Dudek AZ. The role of forkhead box protein M1 in breast cancer progression and resistance to therapy. Int J Breast Cancer. 2016;2016:9768183. doi: 10.1155/2016/9768183. PubMed DOI PMC

Borhani S, Gartel AL. FOXM1: a potential therapeutic target in human solid cancers. Expert Opin. Ther. Targets. 2020;24:205–17. doi: 10.1080/14728222.2020.1727888. PubMed DOI

Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022;10:1367–401. doi: 10.1016/j.gendis.2022.02.007. PubMed DOI PMC

Yao S, Fan LY, Lam EW. The FOXO3-FOXM1 axis: a key cancer drug target and a modulator of cancer drug resistance. Semin Cancer Biol. 2018;50:77–89. doi: 10.1016/j.semcancer.2017.11.018. PubMed DOI PMC

Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radio Oncol. 2019;53:148–58. doi: 10.2478/raon-2019-0018. PubMed DOI PMC

Das T, Anand U, Pandey SK, Ashby CR, Jr, Assaraf YG, Chen ZS, et al. Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updat. 2021;55:100754. doi: 10.1016/j.drup.2021.100754. PubMed DOI

Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, et al. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance. PLoS One. 2014;9:e113478. doi: 10.1371/journal.pone.0113478. PubMed DOI PMC

Xie T, Geng J, Wang Y, Wang L, Huang M, Chen J, et al. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. Oncotarget. 2017;8:8574–89. doi: 10.18632/oncotarget.14351. PubMed DOI PMC

Lin JZ, Wang WW, Hu TT, Zhu GY, Li LN, Zhang CY, et al. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy. Cancer Lett. 2020;469:481–9. doi: 10.1016/j.canlet.2019.11.014. PubMed DOI

Halasi M, Gartel AL. Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage. PLoS One. 2012;7:e31761. doi: 10.1371/journal.pone.0031761. PubMed DOI PMC

Zhou J, Wang Y, Wang Y, Yin X, He Y, Chen L, et al. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLoS One. 2014;9:e96989. doi: 10.1371/journal.pone.0096989. PubMed DOI PMC

Li D, Ye L, Lei Y, Wan J, Chen H. Downregulation of FoxM1 sensitizes nasopharyngeal carcinoma cells to cisplatin via inhibition of MRN-ATM-mediated DNA repair. BMB Rep. 2019;52:208–13. doi: 10.5483/BMBRep.2019.52.3.249. PubMed DOI PMC

Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, et al. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair [published correction appears in Carcinogenesis. 2019 Jul 20;40:936] Carcinogenesis. 2012;33:1843–53. doi: 10.1093/carcin/bgs167. PubMed DOI PMC

Zhang R, Tao F, Ruan S, Hu M, Hu Y, Fang Z, et al. The TGFβ1-FOXM1-HMGA1-TGFβ1 positive feedback loop increases the cisplatin resistance of non-small cell lung cancer by inducing G6PD expression. Am J Transl Res. 2019;11:6860–76. PubMed PMC

Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, Tyner AL, et al. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J. 2009;28:2908–18. doi: 10.1038/emboj.2009.239. PubMed DOI PMC

Choi HJ, Jhe YL, Kim J, Lim JY, Lee JE, Shin MK, et al. FoxM1-dependent and fatty acid oxidation-mediated ROS modulation is a cell-intrinsic drug resistance mechanism in cancer stem-like cells. Redox Biol. 2020;36:101589. doi: 10.1016/j.redox.2020.101589. PubMed DOI PMC

Zhu X, Xue L, Yao Y, Wang K, Tan C, Zhuang M, et al. The FoxM1-ABCC4 axis mediates carboplatin resistance in human retinoblastoma Y-79 cells. Acta Biochim Biophys Sin (Shanghai) 2018;50:914–20. doi: 10.1093/abbs/gmy080. PubMed DOI

Hou Y, Dong Z, Zhong W, Yin L, Li X, Kuerban G, et al. FOXM1 promotes drug resistance in cervical cancer cells by regulating ABCC5 gene transcription. Biomed Res Int. 2022;2022:3032590. doi: 10.1155/2022/3032590. PubMed DOI PMC

Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, et al. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma [published correction appears in BMC Cancer. 2019 Dec 20;19(1):1238] BMC Cancer. 2018;18:1152. doi: 10.1186/s12885-018-5015-0. PubMed DOI PMC

Varghese V, Magnani L, Harada-Shoji N, Mauri F, Szydlo RM, Yao S, et al. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. Sci Rep. 2019;9:1505. doi: 10.1038/s41598-018-38017-0. PubMed DOI PMC

Klinhom-On N, Seubwai W, Sawanyawisuth K, Obchoei S, Mahalapbutr P, Wongkham S. FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. Life Sci. 2021;286:120072. doi: 10.1016/j.lfs.2021.120072. PubMed DOI

Wang K, Zhu X, Zhang K, Zhu L, Zhou F. FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant A549 cells to docetaxel via activation of JNK/mitochondrial pathway. Acta Biochim Biophys Sin (Shanghai) 2016;48:804–9. doi: 10.1093/abbs/gmw072. PubMed DOI

Li X, Yao R, Yue L, Qiu W, Qi W, Liu S, et al. FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin. J Cell Mol Med. 2014;18:811–23. doi: 10.1111/jcmm.12216. PubMed DOI PMC

Khongkow P, Gomes AR, Gong C, Man EP, Tsang JW, Zhao F, et al. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene. 2016;35:990–1002. doi: 10.1038/onc.2015.152. PubMed DOI PMC

Khan I, Kaempf A, Raghuwanshi S, Chesnokov M, Zhang X, Wang Z, et al. Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance. Blood Cancer J. 2023;13:128. doi: 10.1038/s41408-023-00898-4. PubMed DOI PMC

Raghuwanshi S, Gartel AL. Small-molecule inhibitors targeting FOXM1: current challenges and future perspectives in cancer treatments. Biochim Biophys Acta Rev Cancer. 2023;1878:189015. doi: 10.1016/j.bbcan.2023.189015. PubMed DOI

Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006;66:9731–5. doi: 10.1158/0008-5472.CAN-06-1576. PubMed DOI

Katzenellenbogen BS, Guillen VS, Katzenellenbogen JA. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer. Breast Cancer Res. 2023;25:76. doi: 10.1186/s13058-023-01675-8. PubMed DOI PMC

Sullivan C, Liu Y, Shen J, Curtis A, Newman C, Hock JM, et al. Novel interactions between FOXM1 and CDC25A regulate the cell cycle. PLoS One. 2012;7:e51277. doi: 10.1371/journal.pone.0051277. PubMed DOI PMC

Huang S, Hu P, Lakowski TM. Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer. Pharmacogenom J. 2023;23:61–72. doi: 10.1038/s41397-022-00297-1. PubMed DOI PMC

Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8:100789. doi: 10.1016/j.esmoop.2023.100789. PubMed DOI PMC

Lohan-Codeço M, Barambo-Wagner ML, Nasciutti LE, Ribeiro Pinto LF, Meireles Da Costa N, Palumbo A., Jr Molecular mechanisms associated with chemoresistance in esophageal cancer. Cell Mol Life Sci. 2022;79:116. doi: 10.1007/s00018-022-04131-6. PubMed DOI PMC

Kciuk M, Marciniak B, Kontek R. Irinotecan-still an important player in cancer chemotherapy: a comprehensive overview. Int J Mol Sci. 2020;21:4919. doi: 10.3390/ijms21144919. PubMed DOI PMC

Christensen S, Van der Roest B, Besselink N, Janssen R, Boymans S, Martens JWM, et al. 5-Fluorouracil treatment induces characteristic T>G mutations in human cancer. Nat Commun. 2019;10:4571. doi: 10.1038/s41467-019-12594-8. PubMed DOI PMC

Prota AE, Lucena-Agell D, Ma Y, Estevez-Gallego J, Li S, Bargsten K, et al. Structural insight into the stabilization of microtubules by taxanes. Elife. 2023;12:e84791. doi: 10.7554/eLife.84791. PubMed DOI PMC

Yao Y, Wang X, Jiang L, Shao X, Zhu X, He S. Prognostic and clinicopathological value of FoxM1 expression in colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e13899. doi: 10.1097/MD.0000000000013899. PubMed DOI PMC

Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 2020;111:3142–54. doi: 10.1111/cas.14532. PubMed DOI PMC

Yu H, Xu Z, Guo M, Wang W, Zhang W, Liang S, et al. FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A. Cancer Cell Int. 2020;20:545. doi: 10.1186/s12935-020-01631-y. PubMed DOI PMC

Ojima I, Lichtenthal B, Lee S, Wang C, Wang X. Taxane anticancer agents: a patent perspective. Expert Opin Ther Pat. 2016;26:1–20. doi: 10.1517/13543776.2016.1111872. PubMed DOI PMC

Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, et al. Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother. 2023;160:114392. doi: 10.1016/j.biopha.2023.114392. PubMed DOI

Yao J, Deng K, Huang J, Zeng R, Zuo J. Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer. Front Pharmacol. 2020;11:592912. doi: 10.3389/fphar.2020.592912. PubMed DOI PMC

Hamurcu Z, Ashour A, Kahraman N, Ozpolat B. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Oncotarget. 2016;7:16619–35. doi: 10.18632/oncotarget.7672. PubMed DOI PMC

Ogura S, Yoshida Y, Kurahashi T, Egawa M, Furuta K, Kiso S, et al. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. Oncotarget. 2018;9:21022–35. doi: 10.18632/oncotarget.24781. PubMed DOI PMC